CROMA-PHARMA GmbH
CROMA-PHARMA GmbH, a leading player in the pharmaceutical and medical device industry, is headquartered in Austria (AT) and operates extensively across Europe and beyond. Founded in 2003, the company has established itself as a pioneer in the development and distribution of innovative aesthetic and therapeutic solutions, particularly in the fields of dermal fillers and regenerative medicine. CROMA-PHARMA's core products, including the renowned Princess® line of dermal fillers, are distinguished by their high-quality formulations and commitment to safety. The company’s focus on research and development has led to significant advancements in minimally invasive treatments, positioning it as a trusted name among healthcare professionals. With a strong market presence and a dedication to excellence, CROMA-PHARMA continues to achieve notable milestones in enhancing patient care and aesthetic outcomes.
DitchCarbon Score
How does CROMA-PHARMA GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CROMA-PHARMA GmbH's score of 47 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CROMA-PHARMA GmbH's reported carbon emissions
In 2024, CROMA-PHARMA GmbH reported total carbon emissions of approximately 7,247,000 kg CO2e. This includes Scope 1 emissions of about 937,000 kg CO2e, Scope 2 emissions of approximately 768,000 kg CO2e, and significant Scope 3 emissions totalling around 12,764,000 kg CO2e. The Scope 3 emissions breakdown reveals major contributions from capital goods (about 2,009,000 kg CO2e) and upstream transportation and distribution (approximately 1,060,000 kg CO2e). Comparatively, in 2023, the company recorded total emissions of about 7,605,000 kg CO2e, with Scope 1 at approximately 963,000 kg CO2e, Scope 2 at around 804,000 kg CO2e, and Scope 3 emissions reaching about 13,434,000 kg CO2e. This indicates a slight reduction in total emissions year-on-year. CROMA-PHARMA GmbH has set ambitious climate commitments, aiming for net-zero emissions for Scope 1 and Scope 2 by 2035, using 2023 as the baseline year. This target reflects a commitment to reduce emissions by 100% in these scopes. The company is currently classified as a current subsidiary, inheriting its emissions data and climate initiatives directly from its own operations without cascading from a parent organisation. Overall, CROMA-PHARMA GmbH is actively working towards significant emissions reductions while addressing its carbon footprint across all scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 1,081 | 000,000 | 000,000 |
| Scope 2 | 4,516 | 0,000 | 0,000 |
| Scope 3 | 6,452 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CROMA-PHARMA GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
